---
title: "ALNY.US (ALNY.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ALNY.US/news.md"
symbol: "ALNY.US"
name: "ALNY.US"
parent: "https://longbridge.com/en/quote/ALNY.US.md"
datetime: "2026-05-20T19:09:23.297Z"
locales:
  - [en](https://longbridge.com/en/quote/ALNY.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ALNY.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ALNY.US/news.md)
---

# ALNY.US (ALNY.US) — Related News

### [Thrivent Financial for Lutherans Buys New Stake in Alnylam Pharmaceuticals, Inc. $ALNY](https://longbridge.com/en/news/287050595.md)
*2026-05-20T10:49:19.000Z*
> Thrivent Financial for Lutherans acquired a new stake in Alnylam Pharmaceuticals, purchasing 20,641 shares valued at app

### [Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Recommendation of "Moderate Buy" by Analysts](https://longbridge.com/en/news/287033782.md)
*2026-05-20T08:49:17.000Z*
> Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received a consensus rating of 'Moderate Buy' from 26 research firms. An

### [Citigroup is optimistic about the catalysts and growth prospects, covering Ionis, Alnylam, and BioMarin with a buy rating](https://longbridge.com/en/news/286956616.md)
*2026-05-19T19:15:30.000Z*
> Citigroup has initiated coverage on the small and mid-cap biotech sector, giving "Buy" ratings to Ionis, Alnylam, and Bi

### [Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build](https://longbridge.com/en/news/286310602.md)
*2026-05-13T20:14:37.000Z*
> Alnylam Pharmaceuticals CFO Jeff Poulton expressed confidence in the company's TTR revenue guidance, despite a slower gr

### [New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden | ALNY Stock News](https://longbridge.com/en/news/286045693.md)
*2026-05-11T22:30:47.000Z*
> New data analyses presented at Heart Failure 2026 highlight the clinical benefits of Vutrisiran as a first-line treatmen

### [Alnylam rebuked by FDA over efficacy claims on Amvuttra website](https://longbridge.com/en/news/285521285.md)
*2026-05-07T09:34:49.000Z*
> The FDA has issued an untitled letter to Alnylam regarding its Amvuttra website, claiming it presents misleading efficac

### [Pre-market hot trades in US stocks: Alnylam Pharma up 9.59% pre-market; Biodexa Pharmaceuticals down 9.38% pre-market](https://longbridge.com/en/news/285344547.md)
*2026-05-06T09:12:37.000Z*
> Alnylam Pharma pre-market rose 9.59%; Biodexa Pharmaceuticals pre-market fell 9.38%; Entravision Communications pre-mark

### [Bronte Capital Management Pty Ltd. Has $15.45 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY](https://longbridge.com/en/news/285331411.md)
*2026-05-06T07:43:29.000Z*
> Bronte Capital Management Pty Ltd. increased its stake in Alnylam Pharmaceuticals, Inc. by 11.1% in Q4, now holding 38,8

### [Alnylam Pharmaceuticals (ALNY) Valuation After Q1 2026 Profit Breakthrough And Revenue Surge](https://longbridge.com/en/news/285160724.md)
*2026-05-05T06:08:56.000Z*
> Alnylam Pharmaceuticals (ALNY) reported a significant turnaround in Q1 2026, moving from a net loss to a net profit with

### [Research Alert: CFRA Maintains Hold Opinion On Shares Of Alnylam Pharmaceuticals, Inc](https://longbridge.com/en/news/285062203.md)
*2026-05-04T10:55:00.000Z*
> CFRA maintains a hold opinion on Alnylam Pharmaceuticals, lowering the target price to $319 from $340. They raised the 2